3 Results

FDA gives 510(k) approval for the Accula RSV test for diagnosing respiratory syncytial virus.- Mesa Biotech.

 Added 1 month ago

Mesa Biotech announced that it received 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the FDA for its...

AstraZeneca to divest US rights to Synagis to SOBI.

 Added 2 months ago

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection...

Suptavumab (REGN 2222) fails Phase III trial to prevent medically-attended RSV infections in infants.- Regeneron.

 Added 1 year ago

Regeneron Pharmaceuticals, Inc.announced that a Phase III study evaluating suptavumab (REGN 2222), an antibody to respiratory syncytial virus (RSV), did...